A universal multi-drug encapsulation and delivery system employing supramolecular nanogels that self-assemble via dynamic sulfone bonding

一种通用的多药物封装和递送系统,采用通过动态砜键自组装的超分子纳米凝胶

基本信息

  • 批准号:
    10626132
  • 负责人:
  • 金额:
    $ 43.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-08-01 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Significance: Nanostructure formation by supramolecular self-assembly primarily involves the hydrophobic/hydrophilic equilibrium of amphiphiles within aqueous environments. The biocompatibility and chemical versatility permitted by block copolymer amphiphiles have allowed the fabrication of a wide range of nanoscale biomaterials (NBMs). Despite these advances, considerable challenges remain. Self-assembled NBMs experience substantial difficulties with the encapsulation of molecules, with many (often difficult to express or expensive) proteins and hydrophilic small molecules achieving low encapsulation efficiencies well below 20%. Furthermore, the multicomponent structure of these amphiphiles often requires employment of complex block copolymer chemistries, which can present difficulties when scaling up synthesis and purification for practical clinical testing and translation. Innovation: A novel means of supramolecular self-assembly that employs a single, simple, water-soluble homopolymer that achieves >90% encapsulation efficiency universally for multiple hydrophilic (and hydrophobic) small molecules and biologics simultaneously will be modeled, optimized and validated. The unique network self-assembly of poly(propylene sulfone) (PPSU) homopolymers, which are simultaneously both soluble and crystallizable in water, has not been previously reported. By adjusting solvent polarity, intra- and interchain segments of noncovalent sulfone-sulfone bonds form along the PPSU backbone, biomimetic of DNA hybridization and leucine zippers in proteins. Preliminary experiments and simulations of this process revealed dynamic sulfone-sulfone interactions to form an interconnected physical gel network that can solidify into either macroscale hydrogels or collapse into nanogels of diverse morphologies. Using this rapid and scalable methodology, uniform populations of diverse nanogel morphologies can be specified, including spheres, vesicles and filamentous bundles. Importantly, drugs (regardless of their physicochemical properties) are efficiently and universally captured within PPSU nanogels during network collapse. This novel mechanism of molecular encapsulation demonstrates an exceptionally high loading efficiency for all molecules tested and combinations thereof, including proteins, DNA, RNA, fluorophores, contrast agents and small molecule drugs. Two independent aims are proposed to optimize and validate PPSU NBMs as a novel controlled delivery platform for biomedical applications. Aim 1: Employ molecular dynamics simulations and analytical nanoscale microscopy to mechanistically understand PPSU self-assembly and therapeutic loading. Aim 2: Develop universal molecular encapsulation by PPSU as a tool for the optimization of a model NBM vaccine formulation.
项目总结 意义:超分子自组装形成的纳米结构主要涉及 水环境中两亲分子的疏水/亲水平衡。它的生物兼容性和 嵌段共聚物两亲性所允许的化学多样性使其能够制造出广泛的 纳米生物材料(NBM)。尽管取得了这些进展,但仍然存在相当大的挑战。自组装 NBM在分子的封装方面遇到了很大的困难,许多(通常难以表达 或昂贵)蛋白质和亲水性小分子,实现远低于20%的低包封率。 此外,这些两亲分子的多组分结构通常需要使用复杂的嵌段 共聚物化学,这在放大合成和提纯实际应用时会带来困难 临床测试和翻译。 创新:一种新的超分子自组装方法,它使用单一的、简单的、水溶性的 对多种亲水性(和疏水性)具有90%包封率的均聚物 将同时对小分子和生物制品进行建模、优化和验证。独一无二的网络 聚丙基砜(PPSU)均聚体的自组装 可在水中结晶,以前未见报道。通过调整溶剂极性、链内和链间 沿着DNA仿生的PPSU骨架形成非共价的砜-砜键片段 蛋白质中的杂交和亮氨酸拉链。这一过程的初步实验和模拟揭示了 动态的磺酸-磺酸相互作用形成相互连接的物理凝胶网络,该网络可以固化为 大尺度水凝胶或崩塌成不同形貌的纳米凝胶。使用这种快速且可扩展的 方法学,可以指定不同纳米凝胶形态的均匀群体,包括球体、囊泡 和丝状束。重要的是,药物(不管它们的物理化学性质)是有效的和 在网络崩溃期间,在PPSU纳米凝胶中普遍捕获。这一新的分子机制 对于所有测试的分子和组合,封装法显示出极高的负载效率 其中包括蛋白质、DNA、RNA、荧光团、造影剂和小分子药物。 提出了两个独立的目标来优化和验证PPSU NBMS作为一种新型的受控交付平台 用于生物医学应用。目标1:使用分子动力学模拟和分析纳米尺度 显微镜从机械上理解PPSU的自组装和治疗负荷。目标2:发展 PPSU的通用分子封装作为优化模型NBM疫苗配方的工具。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Evan A. Scott其他文献

Efficacy of benznidazole delivery during Chagas disease nanotherapy is dependent on the nanocarrier morphology
在恰加斯病纳米治疗期间,苄硝唑递送的功效取决于纳米载体的形态
  • DOI:
    10.1016/j.biomaterials.2025.123358
  • 发表时间:
    2025-11-01
  • 期刊:
  • 影响因子:
    12.900
  • 作者:
    Debora B. Scariot;Austeja Staneviciute;Rayanne R.B. Machado;Simseok A. Yuk;Yu-Gang Liu;Swagat Sharma;Sultan Almunif;El Hadji Arona Mbaye;Celso Vataru Nakamura;David M. Engman;Evan A. Scott
  • 通讯作者:
    Evan A. Scott
A compact catenane with tuneable mechanical chirality
一种具有可调节机械手性的紧密连接索烃
  • DOI:
    10.1038/s44160-025-00781-z
  • 发表时间:
    2025-04-14
  • 期刊:
  • 影响因子:
    20.000
  • 作者:
    Chun Tang;Ruihua Zhang;Sultan Almunif;Partha Jyoti Das;Paige J. Brown;Ryan M. Young;Guangcheng Wu;Han Han;Xueze Zhao;Arthur H. G. David;Huang Wu;Bo Song;Alexandre Abhervé;Yong Wu;Yu-Meng Ye;Yuanning Feng;Aspen X.-Y. Chen;Charlotte L. Stern;Zhi Li;Evan A. Scott;Michael R. Wasielewski;J. Fraser Stoddart
  • 通讯作者:
    J. Fraser Stoddart

Evan A. Scott的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Evan A. Scott', 18)}}的其他基金

Biomedical Resource Core
生物医学资源核心
  • 批准号:
    10754083
  • 财政年份:
    2023
  • 资助金额:
    $ 43.84万
  • 项目类别:
Identification of the immunomodulatory mechanisms of nanocarrier-enhanced costimulation blockade in an allogeneic portal vein islet transplantation model
异体门静脉胰岛移植模型中纳米载体增强共刺激阻断的免疫调节机制的鉴定
  • 批准号:
    10494100
  • 财政年份:
    2021
  • 资助金额:
    $ 43.84万
  • 项目类别:
Identification of the immunomodulatory mechanisms of nanocarrier-enhanced costimulation blockade in an allogeneic portal vein islet transplantation model
异体门静脉胰岛移植模型中纳米载体增强共刺激阻断的免疫调节机制的鉴定
  • 批准号:
    10303734
  • 财政年份:
    2021
  • 资助金额:
    $ 43.84万
  • 项目类别:
A universal multi-drug encapsulation and delivery system employing supramolecular nanogels that self-assemble via dynamic sulfone bonding
一种通用的多药物封装和递送系统,采用通过动态砜键自组装的超分子纳米凝胶
  • 批准号:
    10457457
  • 财政年份:
    2021
  • 资助金额:
    $ 43.84万
  • 项目类别:
A universal multi-drug encapsulation and delivery system employing supramolecular nanogels that self-assemble via dynamic sulfone bonding
一种通用的多药物封装和递送系统,采用通过动态砜键自组装的超分子纳米凝胶
  • 批准号:
    10298698
  • 财政年份:
    2021
  • 资助金额:
    $ 43.84万
  • 项目类别:
Design and characterization of biomimetic nanobiomaterials to elicit CD1-restricted T cell responses during sub-unit vaccination
仿生纳米生物材料的设计和表征,以在亚单位疫苗接种过程中引发 CD1 限制性 T 细胞反应
  • 批准号:
    10444924
  • 财政年份:
    2019
  • 资助金额:
    $ 43.84万
  • 项目类别:
Design and characterization of biomimetic nanobiomaterials to elicit CD1-restricted T cell responses during sub-unit vaccination
仿生纳米生物材料的设计和表征,以在亚单位疫苗接种过程中引发 CD1 限制性 T 细胞反应
  • 批准号:
    10207410
  • 财政年份:
    2019
  • 资助金额:
    $ 43.84万
  • 项目类别:

相似海外基金

Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate Models
在临床前小鼠和非人灵长类动物模型中确定 A 组链球菌疫苗抗原最有效的佐剂
  • 批准号:
    10577066
  • 财政年份:
    2023
  • 资助金额:
    $ 43.84万
  • 项目类别:
Lymph node-targeted codelivery of albumin-binding peptide antigens and di-adjuvant for melanoma combination immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
  • 批准号:
    10522591
  • 财政年份:
    2022
  • 资助金额:
    $ 43.84万
  • 项目类别:
Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
  • 批准号:
    10884052
  • 财政年份:
    2022
  • 资助金额:
    $ 43.84万
  • 项目类别:
Establishment of postoperative adjuvant immunotherapy using peptide pool of tumor antigens in advanced esophageal cancer
晚期食管癌肿瘤抗原肽库术后辅助免疫治疗的建立
  • 批准号:
    15K10100
  • 财政年份:
    2015
  • 资助金额:
    $ 43.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of cancer vaccine using adjuvant function encrypted artificial antigens
使用佐剂功能加密人工抗原开发癌症疫苗
  • 批准号:
    26430172
  • 财政年份:
    2014
  • 资助金额:
    $ 43.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens
α-半乳糖酰胺作为 HIV 抗原的粘膜佐剂
  • 批准号:
    7849955
  • 财政年份:
    2009
  • 资助金额:
    $ 43.84万
  • 项目类别:
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens
α-半乳糖酰胺作为 HIV 抗原的粘膜佐剂
  • 批准号:
    7627172
  • 财政年份:
    2009
  • 资助金额:
    $ 43.84万
  • 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
  • 批准号:
    2068228
  • 财政年份:
    1992
  • 资助金额:
    $ 43.84万
  • 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
  • 批准号:
    3548034
  • 财政年份:
    1992
  • 资助金额:
    $ 43.84万
  • 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
  • 批准号:
    3548033
  • 财政年份:
    1992
  • 资助金额:
    $ 43.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了